Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that President and CEO Ted White will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on March 9, 2022, at 11:10 a.m. ET. The event will be accessible via a live webcast, and a replay will be available for 30 days post-event. Verrica focuses on developing dermatology therapeutics, including its late-stage product candidate, VP-102, aimed at treating molluscum and common warts, and VP-103 for plantar warts. The company has also licensed LTX-315 for dermatologic oncology.

Positive

• Verrica's VP-102 targets significant unmet needs in dermatology, focusing on conditions like molluscum and common warts.
• Engagement in the Cowen Healthcare Conference enhances visibility and investor relations.

Negative

• None.

WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 42^nd Annual Cowen Virtual Healthcare Conference on Wednesday, March 9, 2022, at 11:10 a.m. ET.

Participants may access a live webcast of the event through the following link:
https://wsw.com/webcast/cowen108/vrca/2011644.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Terry Kohler
Chief Financial Officer
484.453.3296
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com

FAQ

When is Ted White speaking at the Cowen Virtual Healthcare Conference?

Ted White will speak on March 9, 2022, at 11:10 a.m. ET.

How can I access the webcast for Verrica's presentation?

The webcast can be accessed through the provided link or the Investors/Presentations section on Verrica's website.

What is VP-102 and its significance for Verrica Pharmaceuticals?

VP-102 is a late-stage product candidate being developed to address major unmet needs in dermatology, specifically for molluscum and warts.

What other products is Verrica developing?

In addition to VP-102, Verrica is developing VP-103 for plantar warts and has licensed LTX-315 for dermatologic oncology.